VIRGINIA RETIREMENT SYSTEMS ET Al Grows Stock Holdings in Bristol Myers Squibb Company $BMY

VIRGINIA RETIREMENT SYSTEMS ET Al increased its position in Bristol Myers Squibb Company (NYSE:BMY) by 43.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,234,496 shares of the biopharmaceutical company’s stock after buying an additional 679,000 shares during the period. Bristol Myers Squibb comprises approximately 0.7% of VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings, making the stock its 29th largest position. VIRGINIA RETIREMENT SYSTEMS ET Al owned 0.11% of Bristol Myers Squibb worth $100,776,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Trifecta Capital Advisors LLC bought a new position in shares of Bristol Myers Squibb in the second quarter worth about $25,000. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb during the 2nd quarter valued at approximately $25,000. Harbor Capital Advisors Inc. lifted its holdings in Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares in the last quarter. REAP Financial Group LLC boosted its stake in Bristol Myers Squibb by 202.8% in the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 428 shares during the period. Finally, CBIZ Investment Advisory Services LLC grew its holdings in Bristol Myers Squibb by 66.0% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 231 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of research reports. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Guggenheim reiterated a “buy” rating on shares of Bristol Myers Squibb in a research note on Tuesday, December 23rd. Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Scotiabank reaffirmed a “sector perform” rating and issued a $53.00 target price (up from $45.00) on shares of Bristol Myers Squibb in a report on Thursday, December 4th. Finally, Morgan Stanley reiterated an “underweight” rating and issued a $37.00 target price (up from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Six research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $54.62.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $54.22 on Wednesday. The stock has a market cap of $110.38 billion, a price-to-earnings ratio of 18.32, a price-to-earnings-growth ratio of 8.28 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. The stock has a 50 day moving average price of $49.23 and a 200-day moving average price of $47.39. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.Bristol Myers Squibb’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is presently 83.78%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.